Analystreport

Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.

Xeris Biopharma Holdings, Inc.  (XERS) 
Last xeris biopharma holdings, inc. earnings: 3/11 06:00 am Check Earnings Report